Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Pioglitazone with Empagliflozin in Healthy Volunteers
NCT02172235Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2010
- Primary completion
- Jul 2010
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state up to 10 days and Maximum measured concentration at steady state up to 10 days. Started Apr 2010; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02172235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172235.